Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
CareDx
Center for International Blood and Marrow Transplant Research
National Cancer Institute (NCI)
Novartis
M.D. Anderson Cancer Center
Novartis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Groupe Francophone des Myelodysplasies
St. Jude Children's Research Hospital
Cogent Biosciences, Inc.
Orca Biosystems, Inc.
Auron Therapeutics, Inc.
Emory University
Washington University School of Medicine
Incyte Corporation
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Faron Pharmaceuticals Ltd
City of Hope Medical Center
Dartmouth-Hitchcock Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Novartis
Senti Biosciences
National Cancer Institute (NCI)
Novartis
Novartis
Center for International Blood and Marrow Transplant Research
St. Jude Children's Research Hospital
University of Southern California
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
City of Hope Medical Center
St. Jude Children's Research Hospital
City of Hope Medical Center
Dana-Farber Cancer Institute
University of Michigan Rogel Cancer Center
University Health Network, Toronto
M.D. Anderson Cancer Center
Ionis Pharmaceuticals, Inc.
University of Illinois at Chicago